Hubei Biocause Heilen Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Hubei Biocause Heilen Pharmaceutical has been growing earnings at an average annual rate of 3.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 1.3% per year. Hubei Biocause Heilen Pharmaceutical's return on equity is 4.6%, and it has net margins of 23.4%.
Key information
3.9%
Earnings growth rate
-5.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -1.3% |
| Return on equity | 4.6% |
| Net Margin | 23.4% |
| Next Earnings Update | 24 Apr 2025 |
Recent past performance updates
Recent updates
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings
Nov 04
Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211) After Shares Rise 43%
Oct 30Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)
Aug 07Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48
May 22Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations
Apr 29Revenue & Expenses Breakdown
How Hubei Biocause Heilen Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 455 | 106 | 55 | 44 |
| 30 Jun 24 | 499 | 132 | 59 | 52 |
| 31 Mar 24 | 608 | 174 | 61 | 57 |
| 31 Dec 23 | 663 | 176 | 61 | 53 |
| 30 Sep 23 | 712 | 192 | 49 | 40 |
| 30 Jun 23 | 680 | 184 | 53 | 30 |
| 31 Mar 23 | 580 | 138 | 45 | 22 |
| 01 Jan 23 | 515 | 126 | 46 | 20 |
| 30 Sep 22 | 468 | 101 | 56 | 21 |
| 30 Jun 22 | 504 | 108 | 44 | 20 |
| 31 Mar 22 | 548 | 113 | 44 | 20 |
| 01 Jan 22 | 541 | 122 | 40 | 18 |
| 30 Sep 21 | 589 | 138 | 49 | 23 |
| 30 Jun 21 | 576 | 144 | 51 | 25 |
| 31 Mar 21 | 567 | 159 | 63 | 23 |
| 31 Dec 20 | 593 | 168 | 68 | 23 |
| 31 Dec 19 | 660 | 100 | 93 | 25 |
| 31 Dec 18 | 517 | 48 | 83 | 21 |
| 31 Dec 17 | 366 | 10 | 46 | 18 |
Quality Earnings: 301211 has a high level of non-cash earnings.
Growing Profit Margin: 301211's current net profit margins (23.4%) are lower than last year (26.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301211's earnings have grown by 3.9% per year over the past 5 years.
Accelerating Growth: 301211's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 301211 had negative earnings growth (-44.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 301211's Return on Equity (4.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/29 08:40 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hubei Biocause Heilen Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|